Since we first opened our doors in 2013, we have focused single-mindedly on delivering high-quality branded prescription medicines to patients, prescribers and healthcare providers across the globe. We specialise in the late-stage activities of development, co-development, licensing and acquisition.
Within our strategic therapeutic areas, we have developed our own innovative medicines as well as niche speciality products, and we have acquired tried and trusted medicines and iconic brands from innovator pharma companies and breathed new life into them.
From a single office in Basildon, we have grown consistently year on year. This has enabled us to reinvest in our products, our brands, our people, and to give back to our communities.
Our goal is to be an agile and imaginative global specialty pharma business and a preferred partner for innovator pharma companies.
This means that we need to be agile and imaginative, and it also means we need to be a preferred partner for innovator pharma companies.
We focus on late-stage activities to drive growth: developing, licensing and acquiring niche speciality products and established brands within our strategic therapeutic areas. We maintain a simple, lean operating model, working in-depth with our partners.
We develop, license and acquire niche speciality products and established brands.
We ensure these late-stage activities are all strategically complementary at the product and the therapeutic area level.
We market and promote our products through our salesforces in Europe and globally.
We also engage third party salesforces for bespoke and targeted campaigns.
We partner with leading global manufacturers and logistics operators globally.
Our manufacturing network is primarily European and North American, but also covers India and China.
We have in-house expertise to manage all aspects related to product regulatory, quality and technical.
We have significant experience in transfers of manufacturing (known as “technical transfers” or “TTs”), and have a strong track record of delivering in full and on time.
We focus on late-stage activities to drive growth: developing, licensing and acquiring niche speciality products and established brands within our strategic therapeutic areas. We maintain a simple, lean operating model, working in-depth with our partners.
Atnahs Pharma UK Ltd, Sovereign House, Miles Gray Road, Basildon, SS14 3FR, UK
Atnahs Pharma UK Ltd, 13 David Mews, London, W1U 6EQ
Lamepro BV, Burgemeester Guljélaan 2, 4837 CZ Breda, The Netherlands
Pharmanovia A/S, Copenhagen Towers, Oerestads Boulevard 108, DK-2300 Copenhagen S, Denmark
Atnahs Pharma Switzerland AG, Dammstrasse 19, 6300, Zug
Pharmanovia Italy Srl, Milano, Viale Abruzzi n. 94
Atnahs Pharma UK Ltd, Floor 01, Dubai Science Park (DSP) Laboratory Complex, Dubai, UAE
Pharmanovia APAC Pte Ltd, 1 Harbourfront Avenue, #13-03 Keppel Bay Tower, Singapore 098632
Atnahs Pharma Australia Pty Ltd, C/o KPMG, Level 38, Tower 3, International Towers Sydney, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia
Pharmanovia India Private Ltd, Building - Vismay 2, Near GIPCL Circle, New Sama Road, New Sama, Vadodara, Gujarat 390008, India
Pharmanovia Korea Limited, FastFive SAMSEONG BRANCH 3, 12F – PO 1208, Teheran Ro 503, Gangnam Gu Seoul
Benelux site